Home
Immediapress
Pr Newswire
Comunicato stampa - contenuto promozionale
Responsabilità editoriale PrNewswire
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
Mississauga, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026. This strategic
413 words~2 min read
Other newsrooms on this story
· 2 sources
morningstar.com·
Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
